More rapid, robust and sustainable antibody responses to mRNA COVID-19 vaccine in convalescent COVID-19 individuals
Preprint
- 5 August 2021
- preprint
- research article
- Published by Cold Spring Harbor Laboratory
Abstract
Longitudinal studies are needed to evaluate the SARS-CoV-2 mRNA vaccine antibody response under “real-world” conditions. This longitudinal study investigated the quantity and quality of SARS-CoV-2 antibody response in 846 specimens from 350 subjects: comparing BNT162b2-vaccinated individuals (19 previously diagnosed with COVID-19 [RecoVax]; 49 never been diagnosed [NaïveVax]) to 122 hospitalized unvaccinated (HospNoVax) and 160 outpatient unvaccinated (OutPtNoVax) COVID-19 patients.NaïveVax experienced a delay in generating SARS-CoV-2 total antibody levels (TAb) and neutralizing antibodies (SNAb) after the 1st vaccine dose (D1), but a rapid increase in antibody levels was observed after the 2nddose (D2). However, these never reached the robust levels observed in RecoVax. In fact, NaïveVax TAb and SNAb levels decreased 4-weeks post-D2 (p=0.003;p<0.001). For the most part, RecoVax TAb persisted throughout this study, after reaching maximal levels 2-weeks post-D2; but SNAb decreased significantly ∼6-months post-D1 (p=0.002). Although NaïveVax avidity lagged behind that of RecoVax for most of the follow-up periods, NaïveVax did reach similar avidity by ∼6-months post-D1. These data suggest that one vaccine dose elicits maximal antibody response in RecoVax and may be sufficient. Also, despite decreasing levels in TAb and SNAb overtime, long-term avidity maybe a measure worth evaluating and possibly correlating to vaccine efficacy.Keywords
This publication has 44 references indexed in Scilit:
- Phase I/II study of COVID-19 RNA vaccine BNT162b1 in adultsNature, 2020
- SARS-CoV-2-reactive T cells in healthy donors and patients with COVID-19Nature, 2020
- Clinical Characteristics of Covid-19 in New York CityThe New England Journal of Medicine, 2020
- Immunology of COVID-19: Current State of the ScienceImmunity, 2020
- The Incubation Period of Coronavirus Disease 2019 (COVID-19) From Publicly Reported Confirmed Cases: Estimation and ApplicationAnnals of Internal Medicine, 2020
- Potent human neutralizing antibodies elicited by SARS-CoV-2 infectionPublished by Cold Spring Harbor Laboratory ,2020
- An interactive web-based dashboard to track COVID-19 in real timeThe Lancet Infectious Diseases, 2020
- Strategies to guide the antibody affinity maturation processCurrent Opinion in Virology, 2015
- Estimating regression models with unknown break‐pointsStatistics in Medicine, 2003
- Antibody Avidity as a Surrogate Marker of Successful Priming byHaemophilus influenzaeType b Conjugate Vaccines following Infant ImmunizationThe Journal of Infectious Diseases, 1998